Navigation Links
Best Practice Database Adds Research on New Product Commercialization
Date:6/25/2008

CHAPEL HILL, N.C., June 25 /PRNewswire/ -- New research that explores the tactics and strategies that lead to successful product development, launch and management is now available in the Best Practice Database, an online research repository managed by research and consulting firm Best Practices, LLC.

To review sample key findings and key metrics in these studies, go to a landing page with links to each study at this address: http://www3.best-in-class.com/dr319.htm

The Database is an online resource containing more than $30 million in proprietary research conducted on behalf of executives from Fortune 500 companies. You can use this tool to quickly locate studies that identify best practices and metrics in the areas most important to you and your company.

Research added this month to the Best Practice Database includes a benchmarking study on the key success factors in new product commercialization for pharmaceutical and biotechnology companies. Experienced new product commercialization leaders noted that lifecycle management is emerging as a critical new skill in the hands of early-stage marketers. Once the domain of brand teams seeking to manage patent expirations in late-stage products, lifecycle management is taking on new meaning in the early commercialization process. More than ever, early-stage marketers seek to evaluate the full potential of new and existing molecular entities.

Also new to the Database this month are two case studies that deliver insights into the successful product launch of a therapy with a new mechanism of action and reinvigoration of a mature brand.

The new research is available in these Best Practice Database Documents (with ID Number):

-- Best Practices in New Product Commercialization (5001)

-- Requip Case Study: Life Cycle Management - Reinvigorating a Mature Brand (5000)

-- Cymbalta Case Study: Successfully Entering a Crowded Market with a New Mechanism of Action (5002)

To view these studies or other studies in the Database, sign up for our complimentary weekly tour, held on Thursdays at 11 a.m. EDT (GMT-5). To sign up, go to this address: http://www3.best-in-class.com/dw212.htm . If you prefer a different time, simply indicate your preference on the sign up form.

To review abstracts and other information about these studies, go to a landing page with links to each study at this address: http://www3.best-in-class.com/dr319.htm

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, a pharmaceutical research and consulting firm, conducts work based on the principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class organizations. For more information, call 919-403-0251 or visit http://www.best-in-class.com/ .


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Behavioral Risk in the Workplace: Behavioral Risk Management Continues to be an Important Best Practice Area for Employers
2. Martin Memorial Health Systems Selects Allscripts for Electronic Health Record and Practice Management
3. Best Practices: Achieving Excellence in Staffing and Recruiting Methods
4. High-Performing Sales Forces Share Key Practices to Achieve Optimal Performance
5. Kingfisher Healthcare (KFH) Wins Prestigious Frost & Sullivan Best Practices Award
6. Best Practice Database Supports Bio-Pharma M&A Integration with New Publication
7. Edge Health Solutions Releases edgeDMS(TM) 2.0 and edgeMD 2.0(TM), Revolutionary All-in-One Practice Management Software with FDA-Approved Advanced Visualization
8. Rush-Copley Medical Center Selects Allscripts Electronic Health Record and Practice Management Solution
9. Best Practices, LLC: Create Strong Leadership to Add Value to Market Research Function
10. Best Practice Toolkit Supports Recruitment of Top Clinical Investigators
11. Best Practices in Sales Recognition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... As health professionals ... known as “patient engagement.” The patient is doing more than filling out a survey; ... , “There is an increasing emphasis in health care and research on the importance ...
(Date:10/13/2017)... ... 13, 2017 , ... PurhealthRX , a leading Health and Nutrition Company, ... Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market by ... be easily incorporated into liquid products, while reducing costs to end users. , The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017 Halo Labs announces the European launch ... called the HORIZON at MIBio 2017 in Cambridge, U.K ... visible particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity ... novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology: